ALK and non-small cell lung carcinoma: Immunotherapy, specifically ICIs, plays an integral role in NSCLC therapy in patients without actionable mutations such as EGFR, ALK, rearranged during transfection (RET), and ROS proto-oncogene 1 (ROS1) mutations; in these specific mutations, previous studies such as IMMUNOTARGET registry study have shown less ICI efficacy [25].